Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
Absci's AI-driven drug discovery platform is intriguing but remains early-stage, with no commercialized assets and only one candidate in clinical trials. The company faces intense competition, high ...
The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...
The Department of Health and Human Services is set to create two new FDA deputy commissioner positions, one of which will oversee technology and the intersection of health and artificial intelligence, ...
【財華社訊】北京時間2026年8月26日淩晨，美股周二收盤，知名美股漲幅榜前十名分別為Recursion Pharmaceuticals, Inc. Class A(RXRX.US)漲幅+9.54%、Rackspace Technology, Inc.(RXT.US)漲幅+8.97%、Absci Corporation(ABSI.US)漲幅+8.94%、Sana Biotechnology, In ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results